6533b85dfe1ef96bd12be7d3

RESEARCH PRODUCT

Identification and Characterization of a Single High-Affinity Fatty Acid Binding Site in Human Serum Albumin.

Marc NazaréStefan PetryVolker DerdauJulia VolkmarHerman SchreuderLea WenskowskyHans MatterTill Opatz

subject

0301 basic medicineAzolesSerum albuminIbuprofenSerum Albumin HumanMolecular Dynamics Simulation010402 general chemistryCrystallography X-Ray01 natural sciencesCatalysis03 medical and health sciencesProtein DomainsFatty acid bindingmedicineFluorescence Resonance Energy TransferHumansBinding siteBovine serum albuminNitrobenzeneschemistry.chemical_classificationBinding SitesbiologyChemistry010405 organic chemistryFatty AcidsFatty acidGeneral ChemistryGeneral MedicineLigand (biochemistry)Human serum albumin0104 chemical sciencesbody regionsDissociation constant030104 developmental biologyBiochemistryembryonic structuresbiology.proteinWarfarinmedicine.drugProtein Binding

description

A single high-affinity fatty acid binding site in the important human transport protein serum albumin (HSA) is identified and characterized using an NBD (7-nitrobenz-2-oxa-1,3-diazol-4-yl)-C12 fatty acid. This ligand exhibits a 1:1 binding stoichiometry in its HSA complex with high site-specificity. The complex dissociation constant is determined by titration experiments as well as radioactive equilibrium dialysis. Competition experiments with the known HSA-binding drugs warfarin and ibuprofen confirm the new binding site to be different from Sudlow-sites I and II. These binding studies are extended to other albumin binders and fatty acid derivatives. Furthermore an X-ray crystal structure allows locating the binding site in HSA subdomain IIA. The knowledge about this novel HSA site will be important for drug depot development and for understanding drug-protein interaction, which are important prerequisites for modulation of drug pharmacokinetics.

10.1002/anie.201710437https://pubmed.ncbi.nlm.nih.gov/29193545